Onco Actu du 24 avril 2015

	1. Biologie
Brain tumor growth driven by neuronal activity, Stanford-led study finds [Scope Blog] The finding, from a study of mice with human brain tumors, provides a surprising example of an organ’s function driving the growth of tumors within it.
	4. Dépistage, diagnostic et pronostic
How a computer can help your doctor better diagnose cancer [MIT News] Luo emphasizes that such machine-learning models need to be not only accurate but also interpretable to clinicians.
	5.12 Immunothérapies
'Personalised' cancer vaccine moves a step closer [The Independent] The study found that it was possible to generate a strong immune response by generating mRNA vaccines that could recognise several epitope proteins – called polytopes – that stick out from the surface of the targeted tumour cells, the scientists said.
	5.2 Pharma
Crossovers Arm Jounce With $56M For “Next Step” Immuno-Oncology [Xconomy] The company is zeroing in on two things: finding different ways to amp up T cells to attack tumors, and a “next step” cancer immunotherapy approach of drawing out some of the other members of the immune system to fight cancer—macrophages, for instance.
Drug Companies Pin Hopes On TrialReach To Enroll Patients In Clinical Trials Faster [Forbes] Novartis, Pfizer and Eli Lilly are publicly turning over today their technology at a conference in Boston to a London-based start-up called TrialReach.
	5.2.1 Pharma - Partenariats
MedImmune and Juno Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration [Juno Therapeutics] Under the terms of the non-exclusive collaboration, MedImmune and Juno will jointly co-fund the initial Phase Ib study, which is expected to begin later in 2015. The companies will also explore the combination of MEDI4736 with a next-generation, Juno-developed fully human CD19-directed CAR T cell candidate.
AstraZeneca, Juno latest to collaborate on immuno-oncology drugs [Reuters] Under the partnership, MedImmune and Juno will test a combination of their drugs as a potential treatment for patients with non-Hodgkin lymphoma — a type of lymph node cancer.
	5.2.2 Pharma - Fusions & Acquisitions
Clovis Deal Chatter Heats Up Again as Goldman Says Buy: Real M&A [Bloomberg] Clovis is set to present data at the American Society of Clinical Oncology conference in a month that may help further differentiate rociletinib from AstraZeneca’s treatment.
	5.4 Traitements - Economie
Explainer: how does Keytruda treat melanoma and why is it so costly? [The Conversation] More likely, the price is set internationally by what the market is prepared to pay and that is often the American market, which can afford to pay more than many other nations. Australia has little leverage here as it represents less than 1.5% of the world’s pharmaceutical market.
	5.9 AACR
What’s hot as one of cancer’s biggest events draws to a close for another year? [The Institute of Cancer Research] One of the hottest topics at the meeting was the growing excitement around immunotherapies – treatments that harness the power of our immune system to fight cancer. Now it seems the way to further enhance the effects of these drugs is to use them in combination.
	5.9.4 AACR - poumon
AACR 2015: New Subsets of Lung Cancer With KRAS Gene Mutations Identified [The ASCO Post] “Our work revealed three major subsets of KRAS-mutant lung adenocarcinoma, which were dominated by co-occurring genetic events, each biologically distinct and susceptible to different therapeutic strategies.”
	5.9.7 AACR - divers
The study that never existed: cancer edition [HealthNewsReview] In a follow-up post, McBurney wrote that there was, in fact, no presentation of new study data by Byers at the AACR meeting, and that “The entire news cycle linking multivitamin/mineral supplements with cancer risk seems to have been stimulated by the university press release alluding to a commentary published in 2012.”
	6.1 Observation
Study Forecasts New Breast Cancer Cases by 2030 [National Cancer Institute] The study, led by Philip Rosenberg, Ph.D., of NCI’s Division of Cancer Epidemiology and Genetics, confirmed the forecasted increase in U.S. breast cancer cases diagnosed each year, concluding that they will grow from 283,000 cases in 2011 to 441,000 in 2030—a more than 50 percent increase.
Ovary removal may improve breast cancer survival with gene mutation [Reuters] Removing the ovaries was tied to an overall 62% reduced risk of death from the cancer over about 13 years. The apparent benefits were greatest when the removal was done soon after cancer diagnosis.
	6.6 Publications
Study: Peer Review Predicts Success [The Scientist] “The better the score that the [peer-review] committee had assigned, the more likely the grant was to result in a high number of publications, or in publications that are highly cited, or even . . . in research that ultimately gets patented.”
Does peer review ferret out the best science? New study tries to answer [Retraction Watch] Grant reviewers at the U.S. National Institutes of Health are doing a pretty good job of spotting the best proposals and ranking them appropriately, according to a new study in Science out today.